Format
Sort by

Send to

Choose Destination

Search results

Items: 12

1.

Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study.

Schwarz T, Spaczynski M, Kaufmann A, Wysocki J, Gałaj A, Schulze K, Suryakiran P, Thomas F, Descamps D.

BJOG. 2015 Jan;122(1):107-18. doi: 10.1111/1471-0528.13070.

2.

Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.

O'Donoghue ML, Braunwald E, White HD, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP, Im K, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wiviott SD, Bonaca MP, Watson DF, Weaver WD, Serruys PW, Cannon CP; SOLID-TIMI 52 Investigators., Steen DL.

JAMA. 2014 Sep 10;312(10):1006-15. doi: 10.1001/jama.2014.11061. Erratum in: JAMA. 2014 Oct 8;312(14):1473. Dylan P. Steen[corrected to Dylan L. Steen].

3.

Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial.

Punthakee Z, Bosch J, Dagenais G, Diaz R, Holman R, Probstfield J, Ramachandran A, Riddle M, Rydén LE, Zinman B, Afzal R, Yusuf S, Gerstein H; TIDE Trial Investigators..

Diabetologia. 2012 Jan;55(1):36-45. doi: 10.1007/s00125-011-2357-4.

PMID:
22038523
4.

Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years.

Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Schulze K, Poncelet SM, Catteau G, Thomas F, Descamps D.

Hum Vaccin. 2011 Sep;7(9):958-65. doi: 10.4161/hv.7.9.15999.

5.

Persistence of immunity following a booster dose of Haemophilus influenzae type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial.

Khatami A, Snape MD, John T, Westcar S, Klinger C, Rollinson L, Boutriau D, Mesaros N, Wysocki J, Galaj A, Yu LM, Pollard AJ.

Pediatr Infect Dis J. 2011 Mar;30(3):197-202. doi: 10.1097/INF.0b013e3181f728fd.

PMID:
20844459
6.

Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years.

Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Perona P, Poncelet S, Zahaf T, Hardt K, Descamps D, Dubin G; HPV Study Group for Adult Women..

Vaccine. 2009 Jan 22;27(4):581-7. doi: 10.1016/j.vaccine.2008.10.088.

PMID:
19022320
7.

Safety and immunogenicity of a DTaP-IPV(Vero) (serum-free) combination vaccine in comparison to DTaP-IPV(Mkc) when administered simultaneously with Haemophilus influenzae type B conjugate vaccine (PRP-T) in children at 2, 3.5, 5 and 16 months of age.

Pietrzyk JJ, Wysocki J, Pejcz J, Galaj A, Majda-Stanislawska E, Käyhty H, Thierry-Carstensen B, Jensen AM.

Vaccine. 2008 Sep 26;26(41):5296-303. doi: 10.1016/j.vaccine.2008.07.033.

PMID:
18675870
8.

[Comparison of immunogenicity and safety of Engerix B and Twinrix vaccine].

Gałaj A, Grześk G, Borys D, Durmowicz A, Grześk E, Szadujkis-Szadurski L.

Wiad Lek. 2004;57(5-6):217-20. Polish.

PMID:
15518064
9.

[Economic prerequisites of active influenza prevention].

Grześk G, Gałaj A, Korbal P, Durmowicz A, Szadujkis-Szadurski L, Borys D, Grześk E.

Med Pr. 2002;53(4):329-32. Review. Polish.

PMID:
12474413
10.

[Early adverse reactions after vaccination against influenza in chronically ill people].

Gałaj A, Grześk G, Kuziemski A, Szadujkis-Szadurski L, Durmowicz A.

Wiad Lek. 2002;55(7-8):366-72. Polish.

PMID:
12428564
11.

[Adverse reactions after vaccination against influenza in chronically ill people].

Gałaj A, Grześk G, Kuziemski A, Szadujkis-Szadurski L, Sinjab T.

Pol Merkur Lekarski. 2002 Jun;12(72):496-9. Polish.

PMID:
12362669
12.

[Estimation of effectiveness of antiemetic treatment with Zofran given in one dose to children with neoplasms].

Kurylak A, Kurylak D, Masłowska E, Gałaj A, Zawadzka I.

Pediatr Pol. 1995 Nov;70(11):925-8. Polish.

PMID:
8677158
Items per page

Supplemental Content

Loading ...
Support Center